Articles tagged "FK506"

2020 American Transplant Congress
Protective Effect of Fucoidan Against Tacrolimus-Induced Nephrotoxicity in LLC-PK1 Cells
H. J. Jang
Surgery, University of Ulsan, Gangneung Asan Hospital, Gangneung, Korea, Republic of
*Purpose: Tacrolimus (FK506) is an immunosuppressant agent that is frequently used to prevent rejection of solid organs upon transplant. However, nephrotoxicity due to apoptosis and…
2020 American Transplant Congress
The Effects of Rivaroxaban and Apixaban on Tacrolimus Pharmacokinetics
A. C. Scheibner¹, C. Franco-Martinez¹, E. Kincaide¹, R. Hall¹, C. Long²
¹Pharmacotherapy Division, College of Pharmacy, The University of Texas at Austin, University Health System, The University of Texas Health Science Center at San Antonio, San Antonio, TX, ²Feik School of Pharmacy, University of the Incarnate Word, University Health System, The University of Texas Health Science Center at San Antonio, San Antonio, TX
*Purpose: To clarify the pharmacokinetic impact of rivaroxaban (RIVA) and apixaban (APIX) on tacrolimus (TAC) concentrations.*Methods: Solid organ transplant recipients 18-years or older who were…
2020 American Transplant Congress
Envarsus XR Use Can Benefit Serum Creatinine Levels in Vascularized Composite Allotransplantation Patients
C. M. Cooney¹, V. Javia¹, J. Littleton¹, D. S. Cooney¹, R. J. Redett¹, J. T. Shores¹, D. C. Brennan², G. Brandacher¹
¹Plastic and Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, ²Surgery, Johns Hopkins University School of Medicine, Baltimore, MD
*Purpose: Vascularized composite allotransplantation (VCA) is a life-enhancing (as opposed to life-saving) procedure. Therefore, minimizing adverse outcomes associated with chronic immunosuppression is vital to determining…
2020 American Transplant Congress
Activation of Tacrolimus Induced Cytotoxicity Through Apoptotic Pathways
S. Chung, S. Choi
Department of Surgery, Chonnam National University, Gwangju, Korea, Republic of
*Purpose: To elucidate the mechanism of cytotoxicity in FK506-treated Jurkat T cells, signal transduction pathway of TNF-related events was studied.*Methods: Viability of Jurkat T cells…
2020 American Transplant Congress
Imaging OX40+Alloreactive T Cells Provides Early Warning of Organ Transplant Rejection
T. Hirai¹, A. Mayer², T. W. Nobashi², Z. Xiao², T. Udagawa³, K. Seo⁴, F. Simonetta⁵, J. Baker⁵, A. Cheng³, S. S. Gambhir², R. S. Negrin⁵
¹Department of Urology, Tokyo Women's Medical University, Tokyo, Japan, ²Department of Radiology, Stanford University, Stanford, CA, ³Department of Otolaryngology-Head and Neck Surgery, Stanford University, Stanford, CA, ⁴Division of Cardiovascular Medicine, Stanford University, Stanford, CA, ⁵Division of Blood and Marrow Transplantation, Stanford University, Stanford, CA
*Purpose: Diagnosis of organ transplant rejection relies upon biopsy approaches to confirm alloreactive T cell infiltration in the graft. Immuno positron emission tomography (immunoPET) utilizing…
2020 American Transplant Congress
Trust and Transparency in Artificial Intelligence-Aided Immunosuppression Decisions
J. Clement
Information and Decision Sciences, University of Minnesota, Minneapolis, MN
*Purpose: In transplant, there is significant interest in using Artificial Intelligence (including machine learning or predictive models) Clinical Decision Support Systems(AI CDSS). Properly designing and…
2020 American Transplant Congress
Effect of Glecaprevir/Pibrentasvir on Weight-Adjusted Tacrolimus Trough/Dose Ratios in Heart and Kidney Recipients
D. Nnani¹, A. Campbell¹, M. Ajaimy², S. R. Patel³, O. Saeed³, D. J. Goldstein⁴, J. Graham⁵, U. P. Jorde³
¹Pharmacy, Montefiore Medical Center, Bronx, NY, ²Medicine, Montefiore Medical Center, Bronx, NY, ³Division of Cardiology, Department of Medicine, Montefiore Medical Center, Bronx, NY, ⁴Cardiothoracic Surgery, Montefiore Medical Center, Bronx, NY, ⁵Surgery, Montefiore Medical Center, Bronx, NY
*Purpose: An innovative strategy to meet the demands of patients requiring heart or kidney transplantation is the acceptance of hepatitis C viremic organs. Direct acting…
2020 American Transplant Congress
Assessment of Time to Therapeutic Tacrolimus Levels Following Renal Transplantation in a Non-Weight-Based Dosing Model
J. Banbury¹, A. Dodson¹, C. Lin², K. Gutierrez¹
¹University of Alabama at Birmingham Hospital, Birmingham, AL, ²Center for Clinical and Translational Science, University of Alabama at Birmingham, Birmingham, AL
*Purpose: The optimal initial dose for tacrolimus (TAC) after renal transplant (RT) remains controversial with limited evidence comparing weight-based and conservative strategies. Recent literature suggests…
2020 American Transplant Congress
Early Calculation of the Tacrolimus Concentration-to-Dose Ratio Does Not Predict Outcomes after Renal Transplantation
K. Schütte-Nütgen, I. Bartmann, B. Suwelack, S. Reuter
Department of Internal Medicine D, University Hospital Münster, Münster, Germany
*Purpose: There is emerging interest in the concentration-to-dose (C/D) ratio of tacrolimus (Tac) as it is linked to outcomes after renal transplantation (RTx). Recently, we…
2019 American Transplant Congress
Time within Therapeutic Range: A Comparison of Three Tacrolimus Formulations within Ninety Days of Renal Transplant
S. Patel, K. Khalil, A. Lichvar, E. Benedetti, P. West-Thielke
University of Illinois Hospital and Health Sciences System, Chicago, IL
*Purpose: Optimizing tacrolimus (TAC) time within therapeutic range (TTR) has been shown to improve outcomes post-transplant. To date, there are no studies assessing differences in…